BROWSE

Related Scientist

scharer,orlando's photo.

scharer,orlando
유전체항상성연구단
more info

ITEM VIEW & DOWNLOAD

PARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations

DC Field Value Language
dc.contributor.authorAlexander von Werdt-
dc.contributor.authorLaura Brandt-
dc.contributor.authorOrlando D. Scharer-
dc.contributor.authorMark A. Rubin-
dc.date.accessioned2022-06-13T06:19:47Z-
dc.date.available2022-06-13T06:19:47Z-
dc.date.created2021-12-21-
dc.date.issued2021-05-
dc.identifier.issn2473-4284-
dc.identifier.urihttps://pr.ibs.re.kr/handle/8788114/11757-
dc.description.abstract<jats:sec><jats:title>PURPOSE</jats:title><jats:p> With the broad use of next-generation sequencing assays, it has become clear that mutations in DNA repair genes are more commonly found than previously reported. In advanced prostate cancer patients with BRCA1/2 or ATM mutations, poly (ADP-ribose) polymerase inhibition (PARPi) causes an increased overall survival advantage compared with patients without these mutations. This review explores the advantages and limitations of PARPi treatment and its use beyond BRCA1/2-altered tumors. Furthermore, it discusses the benefits of current biomarkers and what role functional biomarkers and organoids may play in addressing the involvement of homologous recombination repair mutations in tumor development and progression. </jats:p></jats:sec><jats:sec><jats:title>METHODS</jats:title><jats:p> A systematic review was conducted in MEDLINE, National Library of Medicine, and ClinicalTrials.gov to identify studies published between January 1, 2016, and August 31, 2021. The search strategy incorporated terms for PARPi, BRCA, DNA damage, homologous recombination, organoids, patient-derived organoids, biomarker AND prostate cancer, breast cancer, ovarian cancer. </jats:p></jats:sec><jats:sec><jats:title>RESULTS</jats:title><jats:p> A total of 261 records remained after duplicate removal, 69 of which were included in the qualitative synthesis. </jats:p></jats:sec><jats:sec><jats:title>CONCLUSION</jats:title><jats:p> To improve the outcome of targeted therapy and increase sensitivity of tumor detection, patients should be repeatedly screened for DNA repair gene alterations and biomarkers. Future clinical studies should explore the use of PARPi beyond BRCA1/2 mutations and focus on finding new synthetically lethal interactions. </jats:p></jats:sec>-
dc.publisherAmerican Society of Clinical Oncology-
dc.titlePARP Inhibition in Prostate Cancer With Homologous Recombination Repair Alterations-
dc.typeArticle-
dc.type.rimsART-
dc.identifier.wosid000757141900009-
dc.identifier.scopusid2-s2.0-85123205328-
dc.identifier.rimsid76945-
dc.contributor.affiliatedAuthorOrlando D. Scharer-
dc.identifier.doi10.1200/po.21.00152-
dc.identifier.bibliographicCitationJCO Precision Oncology, v.5, pp.1639 - 1649-
dc.relation.isPartOfJCO Precision Oncology-
dc.citation.titleJCO Precision Oncology-
dc.citation.volume5-
dc.citation.startPage1639-
dc.citation.endPage1649-
dc.description.journalClass1-
dc.description.journalClass1-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalWebOfScienceCategoryOncology-
dc.subject.keywordPlusBRCA2 MUTATIONS-
dc.subject.keywordPlusBREAST-
dc.subject.keywordPlusPOLYMERASE-
dc.subject.keywordPlusRESISTANCE-
dc.subject.keywordPlusTARGETING DNA-REPAIR-
dc.subject.keywordPlusOUTCOMES-
dc.subject.keywordPlusASSOCIATION-
dc.subject.keywordPlusTHERAPIES-
dc.subject.keywordPlusMODELS-
dc.subject.keywordPlusRISKS-
Appears in Collections:
Center for Genomic Integrity(유전체 항상성 연구단) > 1. Journal Papers (저널논문)
Files in This Item:
There are no files associated with this item.

qrcode

  • facebook

    twitter

  • Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse